Associations of medications used during hospitalization and immunological changes in patients with COVID-19 during 3-month follow-up
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved..
BACKGROUND: Understanding the immunological responses in COVID-19 patients during their recovery period is essential to the development of a vaccine and herd immunity.
METHODS: This retrospective cohort study screened 233 patients admitted to the First Hospital of Changsha, China with COVID-19 from January 17th to February 29th, 2020. After completion of SARS-CoV2-specific immunoglobulins, and T cells tests at 2-week and 3-month follow-up points after discharge, 87 were enrolled. Wilcoxon signed-rank test was performed to assess changes in the values of IgG and IgM, the number of CD3+, CD4+ and CD8+ T cells, and CD4+/CD8+ ratio during the 3-month follow-up. Linear regressions were used to evaluate the associations of immunological changes and medications during hospitalization.
RESULTS: The positive rate of IgG decreased from 98.6% (40/41) to 85.4% (35/41) in men and 100% (43/43) to 76.7% (33/43) in women, whereas IgM declined from 34.1% (14/41) to 12.2% (5/41) in men and 37.2% (16/43) to 27.9% (12/43) in women during the follow-up. CD4+ T cells increased from (median (IQR), 484 (384-635)) cells/ul to 543 (414-657) cells/ul (P = 0.01). Antibiotic use was negatively associated with IgG change (mean change [95%CI], 8.08 [0.80-15.37] U, P = 0.03), and glucocorticoid use was positively related to increased CD4+ T cells (100.85 [16.56-185.15] cells/ul, P = 0.02).
CONCLUSION: This study demonstrated that the positive rates and values of IgG and IgM decreased in COVID-19 patients over a 3-month follow-up, while CD4+ T cells significantly increased. Moreover, we found that antibiotic use during hospitalization was associated with IgG decrease, and glucocorticoid use was associated with increases in CD4+ T cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
International immunopharmacology - 89(2020), Pt A vom: 01. Dez., Seite 107121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Chao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 15.12.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2020.107121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317361503 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317361503 | ||
| 003 | DE-627 | ||
| 005 | 20231225163114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2020.107121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1057.xml |
| 035 | |a (DE-627)NLM317361503 | ||
| 035 | |a (NLM)33168413 | ||
| 035 | |a (PII)S1567-5769(20)33588-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Chao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Associations of medications used during hospitalization and immunological changes in patients with COVID-19 during 3-month follow-up |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Understanding the immunological responses in COVID-19 patients during their recovery period is essential to the development of a vaccine and herd immunity | ||
| 520 | |a METHODS: This retrospective cohort study screened 233 patients admitted to the First Hospital of Changsha, China with COVID-19 from January 17th to February 29th, 2020. After completion of SARS-CoV2-specific immunoglobulins, and T cells tests at 2-week and 3-month follow-up points after discharge, 87 were enrolled. Wilcoxon signed-rank test was performed to assess changes in the values of IgG and IgM, the number of CD3+, CD4+ and CD8+ T cells, and CD4+/CD8+ ratio during the 3-month follow-up. Linear regressions were used to evaluate the associations of immunological changes and medications during hospitalization | ||
| 520 | |a RESULTS: The positive rate of IgG decreased from 98.6% (40/41) to 85.4% (35/41) in men and 100% (43/43) to 76.7% (33/43) in women, whereas IgM declined from 34.1% (14/41) to 12.2% (5/41) in men and 37.2% (16/43) to 27.9% (12/43) in women during the follow-up. CD4+ T cells increased from (median (IQR), 484 (384-635)) cells/ul to 543 (414-657) cells/ul (P = 0.01). Antibiotic use was negatively associated with IgG change (mean change [95%CI], 8.08 [0.80-15.37] U, P = 0.03), and glucocorticoid use was positively related to increased CD4+ T cells (100.85 [16.56-185.15] cells/ul, P = 0.02) | ||
| 520 | |a CONCLUSION: This study demonstrated that the positive rates and values of IgG and IgM decreased in COVID-19 patients over a 3-month follow-up, while CD4+ T cells significantly increased. Moreover, we found that antibiotic use during hospitalization was associated with IgG decrease, and glucocorticoid use was associated with increases in CD4+ T cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunological response | |
| 650 | 4 | |a Medication | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Dun, Yaoshan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a You, Baiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Kongliang |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Huijun |e verfasserin |4 aut | |
| 700 | 1 | |a Ripley-Gonzalez, Jeffrey W |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Suixin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Bo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 89(2020), Pt A vom: 01. Dez., Seite 107121 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2020 |g number:Pt A |g day:01 |g month:12 |g pages:107121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2020.107121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2020 |e Pt A |b 01 |c 12 |h 107121 | ||